Effect	effect	O	O	O	O
of	of	O	O	O	O
intravenous	intravenous	O	O	O	O
metoprolol	metoprolol	CHEMICALS	O	OTHERS	I
or	or	O	O	O	O
intravenous	intravenous	O	O	O	O
metoprolol	metoprolol	CHEMICALS	O	OTHERS	I
plus	plus	O	O	O	O
glucagon	glucagon	O	O	O	O
on	on	O	O	O	O
dobutamine-induced	dobutamine-induced	O	O	O	O
myocardial	myocardial	O	DISEASE	OTHERS	I
ischemia	ischemia	O	DISEASE	OTHERS	I
.	.	O	O	O	O

STUDY	study	O	O	O	O
OBJECTIVE	objective	O	O	O	O
:	:	O	O	O	O
To	to	O	O	O	O
determine	determine	O	O	O	O
the	the	O	O	O	O
effect	effect	O	O	O	O
of	of	O	O	O	O
metoprolol	metoprolol	CHEMICALS	O	OTHERS	I
on	on	O	O	O	O
dobutamine	dobutamine	CHEMICALS	O	OTHERS	I
stress	stress	O	O	O	O
testing	testing	O	O	O	O
with	with	O	O	O	O
technetium-99	technetium-99	O	O	OTHERS	I
m	m	O	O	OTHERS	I
sestamibi	sestamibi	O	O	OTHERS	I
single-photon	single-photon	O	O	O	O
emission	emission	O	O	O	O
computed	computed	O	O	O	O
tomography	tomography	O	O	O	O
imaging	imaging	O	O	O	O
and	and	O	O	O	O
ST-segment	st-segment	O	O	O	O
monitoring	monitoring	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
to	to	O	O	O	O
assess	assess	O	O	O	O
the	the	O	O	O	O
impact	impact	O	O	O	O
of	of	O	O	O	O
intravenous	intravenous	O	O	O	O
glucagon	glucagon	O	O	O	O
on	on	O	O	O	O
metoprolol	metoprolol	CHEMICALS	O	OTHERS	I
's	's	O	O	O	O
effects	effects	O	O	O	O
.	.	O	O	O	O

DESIGN	design	O	O	O	O
:	:	O	O	O	O
Randomized	randomized	O	O	O	O
,	,	O	O	O	O
double-blind	double-blind	O	O	O	O
,	,	O	O	O	O
placebo-controlled	placebo-controlled	O	O	O	O
trial	trial	O	O	O	O
.	.	O	O	O	O

SETTING	setting	O	O	O	O
:	:	O	O	O	O
Community	community	O	O	O	O
hospital	hospital	O	O	O	O
.	.	O	O	O	O

PATIENTS	patients	O	O	O	O
:	:	O	O	O	O
Twenty-two	twenty-two	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
known	known	O	O	O	O
reversible	reversible	O	O	O	O
perfusion	perfusion	O	O	O	O
defects	defects	O	O	O	O
.	.	O	O	O	O

INTERVENTION	intervention	O	O	O	O
:	:	O	O	O	O
Patients	patients	O	O	O	O
underwent	underwent	O	O	O	O
dobutamine	dobutamine	CHEMICALS	O	OTHERS	I
stress	stress	O	O	O	O
tests	tests	O	O	O	O
per	per	O	O	O	O
standard	standard	O	O	O	O
protocol	protocol	O	O	O	O
.	.	O	O	O	O

Before	before	O	O	O	O
dobutamine	dobutamine	CHEMICALS	O	OTHERS	I
was	was	O	O	O	O
begun	begun	O	O	O	O
,	,	O	O	O	O
no	no	O	O	O	O
therapy	therapy	O	O	O	O
was	was	O	O	O	O
given	given	O	O	O	O
during	during	O	O	O	O
the	the	O	O	O	O
first	first	O	O	O	O
visit	visit	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
patients	patients	O	O	O	O
were	were	O	O	O	O
randomized	randomized	O	O	O	O
on	on	O	O	O	O
subsequent	subsequent	O	O	O	O
visits	visits	O	O	O	O
to	to	O	O	O	O
receive	receive	O	O	O	O
metoprolol	metoprolol	CHEMICALS	O	OTHERS	I
or	or	O	O	O	O
metoprolol	metoprolol	CHEMICALS	O	OTHERS	I
plus	plus	O	O	O	O
glucagon	glucagon	O	O	O	O
1	1	O	O	O	O
mg	mg	O	O	OTHERS	I
.	.	O	O	O	O

Metoprolol	metoprolol	CHEMICALS	O	OTHERS	I
was	was	O	O	O	O
dosed	dosed	O	O	O	O
to	to	O	O	O	O
achieve	achieve	O	O	O	O
a	a	O	O	O	O
resting	resting	O	O	O	O
predobutamine	predobutamine	O	O	OTHERS	I
heart	heart	O	O	O	O
rate	rate	O	O	O	O
below	below	O	O	O	O
65	65	O	O	O	O
beats/minute	beats/minute	O	O	O	O
or	or	O	O	O	O
a	a	O	O	O	O
total	total	O	O	O	O
intravenous	intravenous	O	O	O	O
dose	dose	O	O	O	O
of	of	O	O	O	O
20	20	O	O	O	O
mg	mg	O	O	OTHERS	I
.	.	O	O	O	O

MEASUREMENTS	measurements	O	O	O	O
AND	and	O	O	O	O
MAIN	main	O	O	O	O
RESULTS	results	O	O	O	O
:	:	O	O	O	O
Metoprolol	metoprolol	CHEMICALS	O	OTHERS	I
reduced	reduced	O	O	O	O
maximum	maximum	O	O	O	O
heart	heart	O	O	O	O
rate	rate	O	O	O	O
31	31	O	O	O	O
%	%	O	O	O	O
,	,	O	O	O	O
summed	summed	O	O	O	O
stress	stress	O	O	O	O
scores	scores	O	O	O	O
29	29	O	O	O	O
%	%	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
summed	summed	O	O	O	O
difference	difference	O	O	O	O
scores	scores	O	O	O	O
43	43	O	O	O	O
%	%	O	O	O	O
versus	versus	O	O	O	O
control	control	O	O	O	O
.	.	O	O	O	O

Metoprolol	metoprolol	CHEMICALS	O	OTHERS	I
plus	plus	O	O	O	O
glucagon	glucagon	O	O	O	O
also	also	O	O	O	O
reduced	reduced	O	O	O	O
the	the	O	O	O	O
maximum	maximum	O	O	O	O
heart	heart	O	O	O	O
rate	rate	O	O	O	O
29	29	O	O	O	O
%	%	O	O	O	O
versus	versus	O	O	O	O
control	control	O	O	O	O
.	.	O	O	O	O

Summed	summed	O	O	O	O
stress	stress	O	O	O	O
and	and	O	O	O	O
summed	summed	O	O	O	O
difference	difference	O	O	O	O
scores	scores	O	O	O	O
were	were	O	O	O	O
not	not	O	O	O	O
significantly	significantly	O	O	O	O
reduced	reduced	O	O	O	O
,	,	O	O	O	O
although	although	O	O	O	O
they	they	O	O	O	O
were	were	O	O	O	O
18	18	O	O	O	O
%	%	O	O	O	O
and	and	O	O	O	O
30	30	O	O	O	O
%	%	O	O	O	O
lower	lower	O	O	O	O
,	,	O	O	O	O
respectively	respectively	O	O	O	O
,	,	O	O	O	O
than	than	O	O	O	O
control	control	O	O	O	O
.	.	O	O	O	O

No	no	O	O	O	O
significant	significant	O	O	O	O
differences	differences	O	O	O	O
were	were	O	O	O	O
found	found	O	O	O	O
in	in	O	O	O	O
any	any	O	O	O	O
parameter	parameter	O	O	O	O
between	between	O	O	O	O
metoprolol	metoprolol	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
metoprolol-glucagon	metoprolol-glucagon	O	O	O	O
.	.	O	O	O	O

CONCLUSION	conclusion	O	O	O	O
:	:	O	O	O	O
During	during	O	O	O	O
dobutamine	dobutamine	CHEMICALS	O	OTHERS	I
stress	stress	O	O	O	O
testing	testing	O	O	O	O
,	,	O	O	O	O
metoprolol	metoprolol	CHEMICALS	O	OTHERS	I
attenuates	attenuates	O	O	O	O
or	or	O	O	O	O
eliminates	eliminates	O	O	O	O
evidence	evidence	O	O	O	O
of	of	O	O	O	O
myocardial	myocardial	O	DISEASE	OTHERS	I
ischemia	ischemia	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Glucagon	glucagon	O	O	O	O
1	1	O	O	O	O
mg	mg	O	O	OTHERS	I
,	,	O	O	O	O
although	although	O	O	O	O
somewhat	somewhat	O	O	O	O
effective	effective	O	O	O	O
,	,	O	O	O	O
does	does	O	O	O	O
not	not	O	O	O	O
correct	correct	O	O	O	O
this	this	O	O	O	O
effect	effect	O	O	O	O
to	to	O	O	O	O
the	the	O	O	O	O
extent	extent	O	O	O	O
that	that	O	O	O	O
it	it	O	O	O	O
can	can	O	O	O	O
be	be	O	O	O	O
administered	administered	O	O	O	O
clinically	clinically	O	O	O	O
.	.	O	O	O	O

